In re: Abbott Laboratories, et al
Case Number:
23-2412
Court:
Nature of Suit:
Companies
- Abbott Laboratories
- AbbVie Inc.
- Allergan PLC
- Cardinal Health Inc.
- Cencora Inc.
- J.M. Smith Corp.
- McKesson Corp.
- Paddock Laboratories Inc.
- Par Pharmaceutical Cos. Inc.
- Teva Pharmaceutical Industries Ltd.
- The Harvard Drug Group LLC
Sectors & Industries:
-
March 25, 2024
3rd Circ. Won't Rethink AbbVie Privilege Ruling
The Third Circuit refused Monday to reconsider a ruling that found AbbVie was unable to show a lower court went against precedent or made errors when ordering the drugmaker to turn over attorney communications from a patent case allegedly meant to delay an AndroGel rival.
-
March 11, 2024
3rd Circ. Finds No Reason To Disturb AbbVie Privilege Ruling
The Third Circuit has found that AbbVie was unable to show that a Pennsylvania federal court went against precedent or made an error when ordering the drugmaker to turn over attorney communications from a "sham" patent case allegedly meant to delay AndroGel competitors.
-
February 22, 2024
3rd Circ. Won't Protect AbbVie's Atty-Client Communications
The Third Circuit has denied AbbVie Inc.'s bid to block a Pennsylvania federal court's order to turn over attorney communications from a patent case allegedly cooked up just to extend the company's monopoly on a testosterone drug, but the appellate court's explanation remained under seal Thursday.
-
November 29, 2023
AbbVie Tells 3rd Circ. 'Sham' Case Ruling 'Explodes' Privilege
Judges on a Third Circuit panel were skeptical Wednesday of arguments from AbbVie Inc. that a lower court's ruling on discovery of attorney communications in a "sham" patent case would open the floodgates to privilege challenges any time a drug company files a suit that slows down a competitor.